Myriad Corporate Presentation
Myriad Annual Report 2018

News Releases | Subscribe

July 31, 2020

Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

SALT LAKE CITY, July 31, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis ® CDx for men with prostate cancer who are eligible or may become eligible for

Read More

July 29, 2020

Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY™ technology, which further increases the performance of its Prequel™ noninvasive

Read More

July 28, 2020

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra ® test report.

Read More

May 5, 2020

Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results

Total Third-Quarter Revenues of $164.0 Million Third-Quarter Diluted EPS of ($1.55) and Adjusted EPS of ($0.08) SALT LAKE CITY, May 05, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today

Read More

April 28, 2020

Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020

SALT LAKE CITY, April 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal third-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

April 8, 2020

Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic

SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance.

Read More

July 22, 2020

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad’s Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors SALT LAKE CITY, July 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in

Read More

May 28, 2020

Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.

SALT LAKE CITY, May 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel K. Spiegelman, age 61, to its Board of Directors, effective immediately, expanding the Board to nine

Read More

April 28, 2020

Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020

SALT LAKE CITY, April 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal third-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

July 31, 2020

Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

SALT LAKE CITY, July 31, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis ® CDx for men with prostate cancer who are eligible or may become eligible for

Read More

July 29, 2020

Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY™ technology, which further increases the performance of its Prequel™ noninvasive

Read More

July 28, 2020

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra ® test report.

Read More

July 31, 2020

Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

SALT LAKE CITY, July 31, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis ® CDx for men with prostate cancer who are eligible or may become eligible for

Read More

July 29, 2020

Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY™ technology, which further increases the performance of its Prequel™ noninvasive

Read More

July 28, 2020

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra ® test report.

Read More